Cyanidin-3-O-arabinoside

Cyanidin-3-O-arabinoside 是一种 p38 MAPK 磷酸化抑制剂,可降低 VDAC1 表达、抑制 mtROS 积累、逆转细胞衰老、阻断线粒体钙的过度内流、减少线粒体相关内质网膜的形成并抑制 VDAC1-IP3R1 相互作用,同时可激活毛囊干细胞增殖、改善毛发生长减缓的状况,因此可用于结肠癌和雄激素性脱发的相关研究。
产品编号: MS-W15832 纯度: 95.71% CAS No.: 111613-04-8 分子式: C20H19ClO10 分子量: 454.81
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Cyanidin-3-O-arabinoside 是一种 p38 MAPK 磷酸化抑制剂,可降低 VDAC1 表达、抑制 mtROS 积累、逆转细胞衰老、阻断线粒体钙的过度内流、减少线粒体相关内质网膜的形成并抑制 VDAC1-IP3R1 相互作用,同时可激活毛囊干细胞增殖、改善毛发生长减缓的状况,因此可用于结肠癌和雄激素性脱发的相关研究。

生物实验数据

生物活性 Cyanidin-3-O-arabinoside is a p38 MAPK phosphorylation inhibitor that reduces VDAC1 expression, inhibits mtROS accumulation, reverses cellular senescence, blocks excessive mitochondrial calcium influx, decreases mitochondria-associated endoplasmic reticulum membrane formation, and suppresses VDAC1-IP3R1 interaction, while also activating hair follicle stem cell proliferation and ameliorating slowed hair growth, and is therefore applicable to research related to colon cancer and androgenetic alopecia.
IC50 & Target

VDAC1

 

IL-6

 

体外研究
(In Vitro)

Cyanidin-3-O-arabinoside 可与纯化的人源 APN、JAK3 及 EZH2 蛋白产生强结合亲和力。
Cyanidin-3-O-arabinoside (120-320 μg/mL; 24-72 h) 可以浓度和时间依赖的方式强效抑制 Caco-2 细胞增殖。
Cyanidin-3-O-arabinoside (120-280 μg/mL; 72 h) 可诱导 Caco-2 细胞发生浓度依赖性凋亡和细胞周期阻滞,增加 G0/G1 期细胞的积累。
Cyanidin-3-O-arabinoside (120-280 μg/mL; 72 h) 对 Caco-2 细胞中凋亡相关蛋白具有浓度依赖性调控作用,在处理 72 h 后可上调 Bax 的表达并下调 Bcl-2 的表达。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 72 h co-incubation with DHT) 可通过减少 SA-β-gal 阳性细胞数量并抑制衰老标志物 (p21、p16) 的表达,逆转二氢睾酮 (DHT) 诱导的人毛乳头细胞 (DPCs) 衰老。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 48 h co-incubation with DHT) 可有效降低二氢睾酮 (DHT) 诱导的人真皮乳头细胞 (DPCs) 中 mtROS 的积累。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 2 h co-incubation with DHT) 可抑制二氢睾酮 (DHT) 诱导的人毛乳头细胞 (DPCs) 内 ROS 的生成。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 48 h co-incubation with DHT) 可阻断二氢睾酮 (DHT) 诱导的人真皮乳头细胞 (DPCs) 内线粒体钙过度累积。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 24 h co-incubation with DHT) 可通过抑制 VDAC1 表达及 VDAC1-IP3R1 相互作用,降低二氢睾酮 (DHT) 诱导的人毛乳头细胞 (DPCs) 中线粒体相关内质网膜 (MAM) 的形成。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, co-incubation with DHT) 可抑制二氢睾酮 (DHT) 诱导的人毛乳头细胞 (DPCs) 中 AR 转录活性。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 72 h co-incubation with DHT for DPCs) 可生成条件培养基,当用该培养基预处理暴露于二氢睾酮 (DHT) 的人毛乳头细胞 (DPCs) 时,能够恢复人毛囊干细胞 (HFSC) 的增殖并降低 HFSC 衰老标志物的表达。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 24 h co-incubation with DHT for qPCR, 72 h co-incubation with DHT for ELISA) 可在 mRNA 和蛋白水平逆转双氢睾酮 (DHT) 诱导的人真皮乳头细胞 (DPCs) 中毛囊调控因子 (DKK1、TGFB1、IL6) 的上调表达。
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 2 h co-incubation with DHT) 可抑制二氢睾酮 (DHT) 诱导的人毛乳头细胞 (DPCs) 中 p38 丝裂原活化蛋白激酶 (MAPK) 磷酸化及后续的 HSP27 磷酸化。

Cell Proliferation Assay

Cell Line: human colon adenocarcinoma Caco-2 cells
Concentration: 120, 160, 200, 240, 280, 320 μg/mL
Incubation Time: 24, 48, 72 h
Result: Inhibited Caco-2 cell proliferation in a concentration- and time-dependent manner.
Achieved an inhibition rate of 93.5% at 72 h with 320 μg/mL.
Exhibited IC50 values of 227, 124, and 112 μg/mL for 24, 48, and 72 h treatments, respectively.

Apoptosis Analysis

Cell Line: human colon adenocarcinoma Caco-2 cells
Concentration: 120, 160, 200, 240, 280 μg/mL
Incubation Time: 72 h
Result: Induced Caco-2 cell apoptosis in a concentration-dependent manner.
Increased the proportion of late apoptotic cells from 1.3% (untreated) to 40.7% at 280 μg/mL.
Reached a total apoptosis rate of 50% at 280 μg/mL.

Cell Cycle Analysis

Cell Line: human colon adenocarcinoma Caco-2 cells
Concentration: 120, 160, 200, 240, 280 μg/mL
Incubation Time: 72 h
Result: Altered Caco-2 cell cycle distribution in a concentration-dependent manner.
Increased the proportion of cells in G0/G1 phase from 45.1% (untreated) to 73.5% at 280 μg/mL.
Decreased the proportion of cells in S phase from 37.3% (untreated) to 17.3% at 280 μg/mL.

Western Blot Analysis

Cell Line: human colon adenocarcinoma Caco-2 cells
Concentration: 120, 160, 200, 240, 280 μg/mL
Incubation Time: 72 h
Result: Regulated Bcl-2 and Bax protein expression in a concentration-dependent manner.
Increased Bax expression with higher cyanidin-3-O-arabinoside concentrations.
Decreased Bcl-2 expression with higher cyanidin-3-O-arabinoside concentrations.

Cell Proliferation Assay

Cell Line: human dermal papilla cells (DPCs), human hair follicle stem cells (HFSCs)
Concentration: 1 μM
Incubation Time: 30 min (pre-incubation); 72 h (co-incubation with DHT for DPCs); 48 h (HFSC culture with conditioned media)
Result: Reduced the deleterious effect of DHT-treated DPC-conditioned media on HFSC proliferation.
Reversed DHT-induced downregulation of FGF4 and FGF6 in DPC-conditioned media.
Decreased senescence marker (p16, p21) expression in HFSCs exposed to DHT-treated conditioned media.

Western Blot Analysis

Cell Line: human dermal papilla cells (DPCs)
Concentration: 1 μM
Incubation Time: 30 min (pre-incubation); 2 h (co-incubation with DHT)
Result: Reduced DHT-induced phosphorylation of p38, while not significantly affecting phosphorylation of ERK or JNK.
Reversed DHT-induced phosphorylation of HSP27.

Real Time qPCR

Cell Line: human dermal papilla cells (DPCs)
Concentration: 1 μM
Incubation Time: 24 h co-incubation with DHT
Result: Reversed dihydrotestosterone (DHT)-induced upregulation of hair follicle-regulatory factors (DKK1, TGFB1, IL6) in human dermal papilla cells (DPCs) at both mRNA and protein levels.
体内研究
(In Vivo)

Cyanidin-3-O-arabinoside (500 μM;局部给药;每 2 天 1 次;共 19 天) 可通过逆转毛球直径、皮肤厚度、真皮比例及毛囊干细胞增殖能力的降低,恢复雄激素性脱发小鼠模型中由 DHT 诱导的毛发生长减缓。

Animal Model: C57BL/6 (7-week-old male, androgenetic alopecia model via DHT injection + shaving/depilation)
Dosage: 500 μM
Administration: topical; once every 2 days; 19 days
Result: Restored DHT-induced hair growth deceleration.
Reversed DHT-induced reduction in hair bulb diameter, skin thickness, and dermal ratio to levels comparable to non-DHT treated control mice.
Increased normalized fluorescence intensity of Ki67 in hair follicle regions, reversing DHT-induced reduction in Ki67 signal.
性状 固体
颜色 Brown to black

化学信息

分子量 454.81
分子式 C20H19ClO10
CAS No. 111613-04-8

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

Ethanol 中的溶解度 : 4.5 mg/mL (9.89 mM; 超声加热助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol1 mM2.1987 mL10.9936 mL21.9872 mL54.9680 mL
5 mM0.4397 mL2.1987 mL4.3974 mL10.9936 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础